Coastlands Capital LP and related reporting persons filed a Schedule 13G with the SEC on October 26, 2026, disclosing beneficial ownership of 1,355,119 shares of common stock in Kalaris Therapeutics, Inc. as of the October 19, 2026 triggering event.

Key Highlights

  • Shares reported: Each of the five reporting persons disclosed beneficial ownership of 1,355,119 shares of Kalaris Therapeutics common stock (par value $0.0001 per share).
  • Ownership percentage: The 1,355,119 shares represent 5.69% of the class, based on 23,804,981 shares outstanding as of August 4, 2026.
  • Voting and dispositive power: All 1,355,119 shares are held on a shared basis; none of the reporting persons holds sole voting or sole dispositive power over any shares.
  • Shares held directly by: According to the filing, the 1,355,119 shares are held directly by Coastlands Capital Partners LP.
  • Control person: Matthew D. Perry is identified as the control person of Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, and Coastlands Capital LLC.
  • Triggering event date: The date of the event requiring this filing is stated as October 19, 2026.

Coastlands Capital and Matthew D. Perry Report Joint 5.69% Position in Kalaris Therapeutics

According to the Schedule 13G filed October 26, 2026, five affiliated reporting persons -- Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry -- each reported beneficial ownership of 1,355,119 shares of Kalaris Therapeutics, Inc. (NASDAQ:KLRS) common stock. The filing states that Coastlands Capital LP serves as investment adviser to the Partnership, while Coastlands Capital GP LLC is the Partnership's general partner. Coastlands Capital LLC is identified as the general partner of Coastlands Capital LP, and Matthew D. Perry is described as the control person of all four entities.

The filing discloses that all 1,355,119 shares are held directly by Coastlands Capital Partners LP and that each reporting person's ownership is on a shared basis only -- none holds sole voting power or sole dispositive power over any of the shares. The ownership percentage of 5.69% is calculated against 23,804,981 shares of common stock outstanding as of August 4, 2026, a figure the filing attributes to Kalaris Therapeutics' Quarterly Report on Form 10-Q filed August 11, 2026.

The reporting persons are described in the filing as filing jointly but "not as members of a group," and each "disclaims membership in a group." The filing further states that each reporting person "disclaims beneficial ownership of shares of Common Stock except to the extent of that person's pecuniary interest therein." All reporting persons are organized in Delaware, with the exception of Matthew D. Perry, who is identified as a United States citizen. Their principal business address is listed as 601 California Street, Suite 1210, San Francisco, CA 94108.

What Was Disclosed

Coastlands Capital LP and four affiliated persons filed a Schedule 13G reporting shared beneficial ownership of 1,355,119 shares, or 5.69%, of Kalaris Therapeutics, Inc. common stock, triggered by an event on October 19, 2026. All shares are held directly by Coastlands Capital Partners LP.